A pilot study of conformal radiotherapy combined with XXXX -based multimodality therapy in newly diagnosed metastatic @entity1149 .

@entity1 @entity137 @entity5 @entity1149 @entity2 @entity3 @entity3866
OBJECTIVE: @entity2 is the leading cause of @entity5 in the world, particularly in major cities in China. We aimed to determine the benefit of survival and @entity137 of Conformal Radiotherapy (CRT) combined with @entity3866 -based multimodality therapy in newly diagnosed metastatic @entity1149 ( @entity1149 ). @entity1 AND METHODS: Newly diagnosed metastatic @entity1149 @entity1 were treated with CRT and @entity3866 , with or without chemotherapy matched protocol. The @entity1 received CRT with a dose of 30-66Gy. @entity3866 was used at least one 28-day cycle. The primary end point was overall survival (OS). RESULTS: Thirty-two @entity1 were analyzed. The median OS was 517 days. @entity1 with only one @entity3 showed longer survival than @entity1 with multi- @entity3 (986 vs. 380 days, n = 8 vs. 24, p = .009). @entity1 with multiple @entity3 in brain conferred worse survival for @entity1 without and with sole brain @entity3 (321 vs. 700 days, n=11 vs 21, p = .006). There was no significant difference in median survival whether @entity3866 was used as a first-, second- or third-line therapy (380 vs. 700 vs. 310 days, n = 10 vs. 15 vs 7, respectively. p = .179). @entity1 with TTCRT > 90 days had longer OS than @entity1 with TTCRT  <= 90 days (749 vs. 322 days, n = 11 vs. 21, p = .012). @entity1 tolerated treatment with limited Grade 1/2 @entity137 . CONCLUSIONS: In this study, @entity1 with newly diagnosed metastatic @entity1149 had survival benefits when @entity3866 was used combined with CRT. Further prospective trials are needed to derive maximal benefit from the drug treatment.
